Table of Contents Author Guidelines Submit a Manuscript
Prostate Cancer
Volume 2014, Article ID 129582, 9 pages
http://dx.doi.org/10.1155/2014/129582
Research Article

Role of p73 Dinucleotide Polymorphism in Prostate Cancer and p73 Protein Isoform Balance

1Department of Chemistry, Biochemistry & Physics, University of Tampa, Tampa, FL 33606, USA
2Department of Biostatistics, Moffitt Cancer Center, Tampa, FL 33612, USA
3Department of Cancer Epidemiology, Moffitt Cancer Center, 12902 Magnolia Drive, Tampa, FL 33612, USA
4Department of Molecular Oncology, Moffitt Cancer Center, Tampa, FL 33612, USA
5Department of Anatomic Pathology, Moffitt Cancer Center, Tampa, FL 33612, USA
6Genitourinary Program, James Haley VA Hospital, Tampa, FL 33612, USA
7Genitourinary Program, Moffitt Cancer Center, Tampa, FL 33612, USA

Received 10 March 2014; Revised 21 May 2014; Accepted 22 May 2014; Published 6 July 2014

Academic Editor: Scott E. Eggener

Copyright © 2014 L. Michael Carastro et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. Institute NC. Surveillance, Epoidemiology, and End Results program, 2014.
  2. S. A. Siddiqui, B. A. Inman, S. Sengupta et al., “Obesity and survival after radical prostatectomy: a 10-year prospective cohort study,” Cancer, vol. 107, no. 3, pp. 521–529, 2006. View at Publisher · View at Google Scholar · View at Scopus
  3. A. E. Teeter, J. C. Presti Jr., W. J. Aronson et al., “Do nomograms designed to predict biochemical recurrence (BCR) do a better job of predicting more clinically relevant prostate cancer outcomes than BCR? A report from the SEARCH database group,” Urology, vol. 82, no. 1, pp. 53–58, 2013. View at Publisher · View at Google Scholar · View at Scopus
  4. Y. M. Cho, S. J. Jung, N. Cho et al., “Impact of international variation of prostate cancer on a predictive nomogram for biochemical recurrence in clinically localised prostate cancer,” World Journal of Urology, pp. 1–7, 2013. View at Publisher · View at Google Scholar · View at Scopus
  5. V. Iremashvili, M. S. Soloway, L. Pelaez, D. L. Rosenberg, and M. Manoharan, “Comparative validation of nomograms predicting clinically insignificant prostate cancer,” Urology, vol. 81, no. 6, pp. 1202–1208, 2013. View at Publisher · View at Google Scholar · View at Scopus
  6. P. K. Jaiswal, V. Singh, and R. D. Mittal, “Polymorphism at P21 codon 31 and dinucleotide polymorphism of P73 gene and susceptibility to bladder cancer in individuals from North India,” Indian Journal of Human Genetics, vol. 19, no. 3, pp. 293–300, 2013. View at Google Scholar
  7. X. Zhou and C. Wu, “Association of p73 G4C14-A4T14 polymorphisms with genetic susceptibilities to breast cancer: a case-control study,” Medical Oncology, vol. 29, no. 5, pp. 3216–3221, 2012. View at Google Scholar · View at Scopus
  8. X. Zhou, “P73 G4C14-to-A4T14 polymorphisms are positively correlated with triple-negative breast cancer in southwestern China,” Medical Oncology, vol. 30, no. 2, article 515, 2013. View at Publisher · View at Google Scholar · View at Scopus
  9. X.-E. Huang, N. Hamajima, N. Katsuda et al., “Association of p53 Codon Arg72Pro and p73 G4C 14-to-A4T14 at exon 2 genetic polymorphisms with the risk of Japanese breast cancer,” Breast Cancer, vol. 10, no. 4, pp. 307–311, 2003. View at Publisher · View at Google Scholar · View at Scopus
  10. J. C. Ahomadegbe, S. Tourpin, M. Kaghad et al., “Loss of heterozygosity, allele silencing and decreased expression of p73 gene in breast cancers: prevalence of alterations in inflammatory breast cancers,” Oncogene, vol. 19, no. 47, pp. 5413–5418, 2000. View at Google Scholar · View at Scopus
  11. R. Craveiro, I. Bravo, R. Catarino et al., “The role of p73 G4C14-to-A4T14 polymorphism in the susceptibility to cervical cancer,” DNA and Cell Biology, vol. 31, no. 2, pp. 224–229, 2012. View at Publisher · View at Google Scholar · View at Scopus
  12. Y. Niwa, N. Hamajima, Y. Atsuta et al., “Genetic polymorphisms of p73 G4C14-to-A4T14 at exon 2 and p53 Arg72Pro and the risk of cervical cancer in Japanese,” Cancer Letters, vol. 205, no. 1, pp. 55–60, 2004. View at Publisher · View at Google Scholar · View at Scopus
  13. N. Hamajima, K. Matsuo, T. Suzuki et al., “No associations of p73 G4C14-to-A4T14 at exon 2 and p53 Arg72Pro polymorphisms with the risk of digestive tract cancers in Japanese,” Cancer Letters, vol. 181, no. 1, pp. 81–85, 2002. View at Publisher · View at Google Scholar · View at Scopus
  14. A. T. Arfaoui, L. B. M. Kriaa, O. E. A. El Hadj et al., “Association of a p73 exon 2 GC/AT polymorphism with colorectal cancer risk and survival in Tunisian patients,” Virchows Archiv, vol. 457, no. 3, pp. 359–368, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. K. E. Lee, Y. S. Hong, B. G. Kim et al., “P73 G4C14 to A4T14 polymorphism is associated with colorectal cancer risk and survival,” World Journal of Gastroenterology, vol. 16, no. 35, pp. 4448–4454, 2010. View at Publisher · View at Google Scholar · View at Scopus
  16. D. Pfeifer, G. Arbman, and X. F. Sun, “Polymorphism of the p73 gene in relation to colorectal cancer risk and survival,” Carcinogenesis, vol. 26, no. 1, pp. 103–107, 2005. View at Publisher · View at Google Scholar · View at Scopus
  17. Y. Niwa, K. Hirose, K. Matsuo et al., “Association of p73 G4C14-to-A4T14 polymorphism at exon 2 and p53 Arg72Pro polymorphism with the risk of endometrial cancer in Japanese subjects,” Cancer Letters, vol. 219, no. 2, pp. 183–190, 2005. View at Publisher · View at Google Scholar · View at Scopus
  18. H. Ge, Y. M. Wang, Y. Y. Cao et al., “The p73 polymorphisms are not associated with susceptibility to esophageal squamous cell carcinoma in a high incidence region of China,” Diseases of the Esophagus, vol. 20, no. 4, pp. 290–296, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. B. M. Ryan, R. McManus, J. S. Daly et al., “A common p73 polymorphism is associated with a reduced incidence of oesophageal carcinoma,” British Journal of Cancer, vol. 85, no. 10, pp. 1499–1503, 2001. View at Publisher · View at Google Scholar · View at Scopus
  20. G. Li, E. M. Sturgis, L. E. Wang et al., “Association of a p73 exon 2 G4C14-to-A4T14 polymorphism with risk of squamous cell carcinoma of the head and neck,” Carcinogenesis, vol. 25, no. 10, pp. 1911–1916, 2004. View at Publisher · View at Google Scholar · View at Scopus
  21. P. Gallì, G. Cadoni, M. Volante et al., “A case-control study on the combined effects of p53 and p73 polymorphisms on head and neck cancer risk in an Italian population,” BMC Cancer, vol. 9, article 137, 2009. View at Publisher · View at Google Scholar · View at Scopus
  22. X. Chen, E. M. Sturgis, A. K. El-Naggar, Q. Wei, and G. Li, “Combined effects of the p53 codon 72 and p73 G4C14-to-A4T14 polymorphisms on the risk of HPV16-associated oral cancer in never-smokers,” Carcinogenesis, vol. 29, no. 11, pp. 2120–2125, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. C. Misra, M. Majumder, S. Bajaj, S. Ghosh, B. Roy, and S. Roychoudhury, “Polymorphisms at p53, p73, and MDM2 loci modulate the risk of tobacco associated leukoplakia and oral cancer,” Molecular Carcinogenesis, vol. 48, no. 9, pp. 790–800, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. Z. Wang, E. M. Sturgis, W. Guo et al., “Association of combined p73 and p53 genetic variants with tumor HPV16-positive oropharyngeal cancer,” PLoS ONE, vol. 7, no. 4, Article ID e35522, 2012. View at Publisher · View at Google Scholar · View at Scopus
  25. E. De Feo, R. Persiani, A. La Greca et al., “A case-control study on the effect of p53 and p73 gene polymorphisms on gastric cancer risk and progression,” Mutation Research, vol. 675, no. 1-2, pp. 60–65, 2009. View at Publisher · View at Google Scholar · View at Scopus
  26. B. Deng, F. Liu, Y. Wei et al., “Association of a p73 exon 2 G4C14-to-A4T14 polymorphism with risk of hepatocellular carcinoma in a Chinese population,” Tumor Biology, vol. 34, no. 1, pp. 293–299, 2013. View at Publisher · View at Google Scholar · View at Scopus
  27. X. Zhang, X. Li, Z. Wu, F. Lin, and H. Zhou, “The p73 G4C14-to-A4T14 polymorphism is associated with risk of lung cancer in the Han nationality of North China,” Molecular Carcinogenesis, vol. 52, no. 5, pp. 387–391, 2013. View at Publisher · View at Google Scholar · View at Scopus
  28. G. Li, L. E. Wang, R. M. Chamberlain, C. I. Amos, M. R. Spitz, and Q. Wei, “p73 G4C14-to-A4T14 polymorphism and risk of lung cancer,” Cancer Research, vol. 64, no. 19, pp. 6863–6866, 2004. View at Publisher · View at Google Scholar · View at Scopus
  29. Z. Hu, X. Miao, H. Ma et al., “Dinucleotide polymorphism of p73 gene is associated with a reduced risk of lung cancer in a Chinese population,” International Journal of Cancer, vol. 114, no. 3, pp. 455–460, 2005. View at Publisher · View at Google Scholar · View at Scopus
  30. J. E. Choi, H. G. Kang, M. H. Chae et al., “No association between p73 G4C14-to-A4T14 polymorphism and the risk of lung cancer in a Korean population,” Biochemical genetics, vol. 44, no. 11-12, pp. 543–550, 2006. View at Google Scholar · View at Scopus
  31. H. J. Jun, S. H. Park, W. K. Lee et al., “Combined effects of p73 and MDM2 polymorphisms on the risk of lung cancer,” Molecular Carcinogenesis, vol. 46, no. 2, pp. 100–105, 2007. View at Google Scholar
  32. M. B. Schabath, X. Wu, Q. Wei, G. Li, J. Gu, and M. R. Spitz, “Combined effects of the p53 and p73 polymorphisms on lung cancer risk,” Cancer Epidemiology Biomarkers and Prevention, vol. 15, no. 1, pp. 158–161, 2006. View at Publisher · View at Google Scholar · View at Scopus
  33. A. Hiraki, K. Matsuo, N. Hamajima et al., “Different risk relations with smoking for non-small-cell lung cancer: comparison of TP53 and TP73 genotypes,” Asian Pacific Journal of Cancer Prevention, vol. 4, no. 2, pp. 107–112, 2003. View at Google Scholar · View at Scopus
  34. A. Hishida, K. Matsuo, K. Tajima et al., “Polymorphisms of p53 Arg72Pro, p73 G4C14-to-A4T14 at exon 2 and p21 Ser31Arg and the risk of non-Hodgkin's lymphoma in Japanese,” Leukemia and Lymphoma, vol. 45, no. 5, pp. 957–964, 2004. View at Publisher · View at Google Scholar · View at Scopus
  35. C. Li, K. Chen, Z. Liu et al., “Polymorphisms of TP53 Arg72Pro, but not p73 G4C14>A4TA4 and p21 Ser31Arg, contribute to risk of cutaneous melanoma,” Journal of Investigative Dermatology, vol. 128, no. 6, pp. 1585–1588, 2008. View at Publisher · View at Google Scholar · View at Scopus
  36. S. Kang, D. J. Wang, W. S. Li et al., “Association of p73 and MDM2 polymorphisms with the risk of epithelial ovarian cancer in Chinese women,” International Journal of Gynecological Cancer, vol. 19, no. 4, pp. 572–577, 2009. View at Publisher · View at Google Scholar · View at Scopus
  37. R. D. Mittal, G. P. George, J. Mishra, T. Mittal, and R. Kapoor, “Role of functional polymorphisms of P53 and P73 genes with the risk of prostate cancer in a case-control study from Northern India,” Archives of Medical Research, vol. 42, no. 2, pp. 122–127, 2011. View at Publisher · View at Google Scholar · View at Scopus
  38. L. Wang, R. Gao, and L. Yu, “Combined analysis of the association between p73 G4C14-to-A4T14 polymorphisms and cancer risk,” Molecular Biology Reports, vol. 39, no. 2, pp. 1731–1738, 2012. View at Publisher · View at Google Scholar · View at Scopus
  39. X. J. Yu, F. Fang, and J. Xie, “Relationship between TP73 polymorphism (G4C14-A4T14) and cancer risk: a meta-analysis based on literatures,” Gene, vol. 484, no. 1-2, pp. 42–46, 2011. View at Publisher · View at Google Scholar · View at Scopus
  40. F. Liu, L. Liu, B. Li et al., “p73 G4C14-A4T14 polymorphism and cancer risk: a meta-analysis based on 27 case-control studies,” Mutagenesis, vol. 26, no. 4, pp. 573–581, 2011. View at Publisher · View at Google Scholar · View at Scopus
  41. Y. Hu, L. Jiang, J. Zheng, Y. You, Y. Zhou, and S. Jiao, “Association between the p73 exon 2 G4C14-to-A4T14 polymorphism and cancer risk: a meta-analysis,” DNA and Cell Biology, vol. 31, no. 2, pp. 230–237, 2012. View at Publisher · View at Google Scholar · View at Scopus
  42. F. Murray-Zmijewski, D. P. Lane, and J.-C. Bourdon, “p53/p63/p73 isoforms: an orchestra of isoforms to harmonise cell differentiation and response to stress,” Cell Death and Differentiation, vol. 13, no. 6, pp. 962–972, 2006. View at Publisher · View at Google Scholar · View at Scopus
  43. M. Marabese, F. Vikhanskaya, and M. Broggini, “p73: a chiaroscuro gene in cancer,” European Journal of Cancer, vol. 43, no. 9, pp. 1361–1372, 2007. View at Publisher · View at Google Scholar · View at Scopus
  44. S. G. Bailey, M. S. Cragg, and P. A. Townsend, “Family friction as Δnp73 antagonises p73 and p53,” International Journal of Biochemistry and Cell Biology, vol. 43, no. 4, pp. 482–486, 2011. View at Publisher · View at Google Scholar · View at Scopus
  45. A. I. Zaika, N. Slade, S. H. Erster et al., “δNp73, a dominant-negative inhibitor of wild-type p53 and TAp73, is up-regulated in human tumors,” Journal of Experimental Medicine, vol. 196, no. 6, pp. 765–780, 2002. View at Publisher · View at Google Scholar · View at Scopus
  46. J. P. Fine and R. J. Gray, “A proportional hazards model for the subdistribution of a competing risk,” Journal of the American Statistical Association, vol. 94, no. 446, pp. 496–509, 1999. View at Google Scholar · View at Scopus
  47. D. A. Arvanitis, E. Lianos, N. Soulitzis, D. Delakas, and D. A. Spandidos, “Deregulation of p73 isoform equilibrium in benign prostate hyperplasia and prostate cancer,” Oncology Reports, vol. 12, no. 5, pp. 1131–1137, 2004. View at Google Scholar · View at Scopus
  48. M. Guan and Y. Chen, “Aberrant expression of ΔNp73 in benign and malignant tumours of the prostate: correlation with Gleason score,” Journal of Clinical Pathology, vol. 58, no. 11, pp. 1175–1179, 2005. View at Publisher · View at Google Scholar · View at Scopus
  49. A. T. Arfaoui, L. K. B. Mahmoud, A. B. Hmida et al., “Relationship between p73 polymorphism and the immunohistochemical profile of the full-length (TAp73) and NH2-truncated (ΔNp73) isoforms in Tunisian patients,” Applied Immunohistochemistry and Molecular Morphology, vol. 18, no. 6, pp. 546–554, 2010. View at Publisher · View at Google Scholar · View at Scopus